NexCAR 19, Indias first cell therapy to treat a specific form of blood cancer, is showing encouraging results. Now listed at 40 hospitals across the country, its indigenous maker, ImmunoACT, is driving a medical revolution. Can the battle against the emperor of all maladies be won?
Caron A. Jacobson, MD, and Miguel-Angel Perales, MD, discuss different uses for CAR T-cell therapy, particularly a trial in which a CAR T-Cell therapy is being evaluated in MRD-positive patients treated with chemotherapy.
Thought leaders discuss patient scenarios and different factors to consider when deciding how to select and utilize bridging therapy in the management of patients with LBCL.
A roundtable discussion on the evolving treatment landscape surrounding CAR T-cell therapy in multiple myeloma, with a focus on future directions and the management of adverse events.